MedTrace Logo

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

NCT04296461 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-01-22

No results posted yet for this study

Summary

This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).

Conditions

  • B-cell Non-Hodgkin Lymphoma

Interventions

GENETIC

Welgenaleucel

Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.

Sponsors & Collaborators

  • Tri-Service General Hospital

    collaborator OTHER

  • UWELL Biopharma

    lead INDUSTRY

Principal Investigators

  • Ching-Liang Ho, MD · Tri-Service General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-27
Primary Completion
2021-06-30
Completion
2021-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04296461 on ClinicalTrials.gov